Search

Your search keyword '"Schmidt-Hegemann, Nina-Sophie"' showing total 280 results
Start Over Author "Schmidt-Hegemann, Nina-Sophie"
280 results on '"Schmidt-Hegemann, Nina-Sophie"'

1. Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis

Author

Trapp, Christian, Aebersold, Daniel M., Belka, Claus, Casuscelli, Jozefina, Emmett, Louise, Eze, Chukwuka, Fanti, Stefano, Farolfi, Andrea, Fendler, Wolfgang, Grosu, Anca-Ligia, Guckenberger, Matthias, Hruby, George, Kirste, Simon, Koerber, Stefan A., Kroeze, Stephanie, Peeken, Jan C., Rogowski, Paul, Scharl, Sophia, Shelan, Mohamed, Spohn, Simon K. B., Strouthos, Iosif, Unterrainer, Lena, Vogel, Marco, Wiegel, Thomas, Zamboglou, Constantinos, and Schmidt-Hegemann, Nina-Sophie

Published
2024
Full Text
View/download PDF

2. Implementation of PET/CT in radiation oncology—a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology

Author

Wegen, Simone, Nestle, Ursula, Zamboglou, Constantinos, Spohn, Simon K. B., Nicolay, Nils Henrik, Unterrainer, Lena M., Koerber, Stefan A., La Fougère, Christian, Fokas, Emmanouil, Kobe, Carsten, Eze, Chukwuka, Grosu, Anca-Ligia, Fendler, Wolfgang P., Holzgreve, Adrien, Werner, Rudolf, and Schmidt-Hegemann, Nina-Sophie

Published
2024
Full Text
View/download PDF

3. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.

Author

Holzgreve, Adrien, Unterrainer, Marcus, Adams, Thaiza, Oprea-Lager, Daniela, Goffin, Karolien, Lopci, Egesta, Unterrainer, Lena, Kramer, Kristina, Schmidt-Hegemann, Nina-Sophie, Casuscelli, Jozefina, Stief, Christian, Ricke, Jens, Bartenstein, Peter, Kunz, Wolfgang, Mehrens, Dirk, and Calais, Jeremie

Subjects
Cost-effectiveness analysis, PSMA PET/CT, Primary staging, ProPSMA trial, Prostate cancer, Male, Humans, Positron Emission Tomography Computed Tomography, Cost-Benefit Analysis, Gallium Radioisotopes, Australia, Prostatic Neoplasms, Neoplasm Staging
Abstract

PURPOSE: The proPSMA trial at ten Australian centers demonstrated increased sensitivity and specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status in primary high-risk prostate cancer patients. A cost-effectiveness analysis showed benefits of PSMA PET/CT over conventional imaging for the Australian setting. However, comparable data for other countries are lacking. Therefore, we aimed to verify the cost-effectiveness of PSMA PET/CT in several European countries as well as the USA. METHODS: Clinical data on diagnostic accuracy were derived from the proPSMA trial. Costs for PSMA PET/CT and conventional imaging were taken from reimbursements of national health systems and individual billing information of selected centers in Belgium, Germany, Italy, the Netherlands, and the USA. For comparability, scan duration and the decision tree of the analysis were adopted from the Australian cost-effectiveness study. RESULTS: In contrast to the Australian setting, PSMA PET/CT was primarily associated with increased costs in the studied centers in Europe and the USA. Mainly, the scan duration had an impact on the cost-effectiveness. However, costs for an accurate diagnosis using PSMA PET/CT seemed reasonably low compared to the potential consequential costs of an inaccurate diagnosis. CONCLUSION: We assume that the use of PSMA PET/CT is appropriate from a health economic perspective, but this will need to be verified by a prospective evaluation of patients at initial diagnosis.

Published
2023

4. Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study

Author

Zinn, Annemarie Barbara, Kenndoff, Saskia, Holzgreve, Adrien, Käsmann, Lukas, Guggenberger, Julian Elias, Hering, Svenja, Mansoorian, Sina, Schmidt-Hegemann, Nina-Sophie, Reinmuth, Niels, Tufman, Amanda, Dinkel, Julien, Manapov, Farkhad, Belka, Claus, and Eze, Chukwuka

Published
2024
Full Text
View/download PDF

7. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Author

Adebahr, Sonja, Althaus, Alexander, Scharl, Sophia, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M. E., Vrachimis, Alexis, Spohn, Simon K. B., Grosu, Anca-Ligia, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Aebersold, Daniel M., Wiegel, Thomas, Afshar-Oromieh, Ali, Zamboglou, Constantinos, and Shelan, Mohamed

Published
2024
Full Text
View/download PDF

8. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy

Author

Scharl, Sophia, Zamboglou, Constantinos, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Koerber, Stefan A., Debus, Jürgen, Peeken, Jan C., Vogel, Marco M.E., Kroeze, Stephanie G.C., Guckenberger, Matthias, Krafcsik, Manuel, Hruby, George, Emmett, Louise, Schmidt-Hegemann, Nina-Sophie, Trapp, Christian, Spohn, Simon K.B., Henkenberens, Christoph, Mayer, Benjamin, Shelan, Mohamed, Aebersold, Daniel M., Thamm, Reinhard, and Wiegel, Thomas

Published
2024
Full Text
View/download PDF

10. Radiotherapy of oligometastatic prostate cancer: a systematic review

Author

Rogowski, Paul, Roach, Mack, Schmidt-Hegemann, Nina-Sophie, Trapp, Christian, von Bestenbostel, Rieke, Shi, Run, Buchner, Alexander, Stief, Christian, Belka, Claus, and Li, Minglun

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Prostate Cancer, Biomedical Imaging, Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Bone Neoplasms, Humans, Lymph Nodes, Lymphatic Metastasis, Male, Prostatic Neoplasms, Radiosurgery, Radiotherapy Dosage, ENRT, Metastasis‐directed therapy, Oligometastatic prostate cancer, Radiotherapy, SBRT, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundDue to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease: (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients.MethodsA systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivity, as well as pattern of recurrence.FindingsEvidence consists largely of retrospective case series and no consistent precise definition of oligometastasis exists, however, most investigators seem to acknowledge the need to distinguish between patients presenting with what is frequently called "synchronous" versus "metachronous" oligometastatic disease. Available data on radiotherapy as MDT demonstrate high local control rates and a small but relevant proportion of patients without progressive disease after 2 years. This holds true for both hormone sensitive and castration resistant prostate cancer diseases. The use of 68Ga-PSMA PET/CT for staging increased dramatically. Radiation doses and field sizes varied considerably among the studies. The search for relevant prognostic and predictive factors is ongoing.ConclusionsTo our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.

Published
2021

11. Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy

Author

Spohn, Simon K. B., Schmidt-Hegemann, Nina-Sophie, Ruf, Juri, Mix, Michael, Benndorf, Matthias, Bamberg, Fabian, Makowski, Marcus R., Kirste, Simon, Rühle, Alexander, Nouvel, Jerome, Sprave, Tanja, Vogel, Marco M. E., Galitsnaya, Polina, Gschwend, Jürgen E., Gratzke, Christian, Stief, Christian, Löck, Steffen, Zwanenburg, Alex, Trapp, Christian, Bernhardt, Denise, Nekolla, Stephan G., Li, Minglun, Belka, Claus, Combs, Stephanie E., Eiber, Matthias, Unterrainer, Lena, Unterrainer, Marcus, Bartenstein, Peter, Grosu, Anca-L., Zamboglou, Constantinos, and Peeken, Jan C.

Published
2023
Full Text
View/download PDF

12. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml

Author

Solomonidou, Nantia, Germanou, Daphnie, Strouthos, Iosif, Karagiannis, Efstratios, Farolfi, Andrea, Koerber, Stefan A., Debus, Juergen, Peeken, Jan C., Vogel, Marco E., Vrachimis, Alexis, Spohn, Simon K. B., Shelan, Mohamed, Aebersold, Daniel, Grosu, Anca-Ligia, Ceci, Francesco, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Belka, Claus, Hruby, George, Scharl, S., Wiegel, Thomas, Bartenstein, Peter, Henkenberens, Christoph, Emmett, Louise, Schmidt-Hegemann, Nina Sophie, Ferentinos, Konstantinos, and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

14. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis

Author

Spohn, Simon K. B., Farolfi, Andrea, Schandeler, Sarah, Vogel, Marco M. E., Ruf, Juri, Mix, Michael, Kirste, Simon, Ceci, Francesco, Fanti, Stefano, Lanzafame, Helena, Serani, Francesca, Gratzke, Christian, Sigle, August, Combs, Stephanie E., Bernhardt, Denise, Gschwend, Juergen E., Buchner, Josef A., Trapp, Christian, Belka, Claus, Bartenstein, Peter, Unterrainer, Lena, Unterrainer, Marcus, Eiber, Matthias, Nekolla, Stephan G., Schiller, Kilian, Grosu, Anca L., Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantinos, and Peeken, Jan C.

Published
2022
Full Text
View/download PDF

15. Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus

Author

Spohn, Simon K.B., Draulans, Cédric, Kishan, Amar U., Spratt, Daniel, Ross, Ashley, Maurer, Tobias, Tilki, Derya, Berlin, Alejandro, Blanchard, Pierre, Collins, Sean, Bronsert, Peter, Chen, Ronald, Pra, Alan Dal, de Meerleer, Gert, Eade, Thomas, Haustermans, Karin, Hölscher, Tobias, Höcht, Stefan, Ghadjar, Pirus, Davicioni, Elai, Heck, Matthias, Kerkmeijer, Linda G.W., Kirste, Simon, Tselis, Nikolaos, Tran, Phuoc T., Pinkawa, Michael, Pommier, Pascal, Deltas, Constantinos, Schmidt-Hegemann, Nina-Sophie, Wiegel, Thomas, Zilli, Thomas, Tree, Alison C., Qiu, Xuefeng, Murthy, Vedang, Epstein, Jonathan I., Graztke, Christian, Gao, Xin, Grosu, Anca L., Kamran, Sophia C., and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

16. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Author

Scharl, Sophia, Zamboglou, Constantinos, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Giuseppe Morganti, Alessio, Trapp, Christian, Koerber, Stefan A., Debus, Jürgen, Peeken, Jan C., Vogel, Marco M.E., Vrachimis, Alexis, Spohn, Simon K.B., Ruf, Juri, Grosu, Anca-Ligia, Ceci, Francesco, Fendler, Wolfgang P., Bartenstein, Peter, Kroeze, Stephanie G.C., Guckenberger, Matthias, Krafcsik, Manuel, Klopscheck, Christina, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Stief, Christian, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Mayer, Benjamin, Miksch, Jonathan, Shelan, Mohamed, Aebersold, Daniel M., Thamm, Reinhard, and Wiegel, Thomas

Published
2023
Full Text
View/download PDF

22. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy

Author

Zamboglou, Constantinos, Strouthos, Iosif, Sahlmann, Joerg, Farolfi, Andrea, Serani, Francesca, Medici, Federica, Cavallini, Letizia, Morganti, Alessio Guiseppe, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M.E., Schiller, Kilian, Combs, Stephanie E., Eiber, Matthias, Vrachimis, Alexis, Ferentinos, Konstantinos, Spohn, Simon K.B., Kirste, Simon, Gratzke, Christian, Ruf, Juri, Grosu, Anca-Ligia, Ceci, Francesco, Fendler, Wolfgang P., Miksch, Jonathan, Kroeze, Stephanie, Guckenberger, Matthias, Lanzafame, Helena, Fanti, Stefano, Hruby, George, Wiegel, Thomas, Emmett, Louise, Schmidt-Hegemann, Nina Sophie, and Henkenberens, Christoph

Published
2022
Full Text
View/download PDF

26. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries: A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO)

Author

Shelan, Mohamed, Aebersold, Daniel M., Albrecht, Clemens, Böhmer, Dirk, Flentje, Michael, Ganswindt, Ute, Höcht, Stefan, Hölscher, Tobias, Müller, Arndt-Christian, Niehoff, Peter, Pinkawa, Michael, Schmidt-Hegemann, Nina-Sophie, Sedlmayer, Felix, Wolf, Frank, Zamboglou, Constantinos, Zips, Daniel, Wiegel, Thomas, and Ghadjar, Pirus

Published
2021
Full Text
View/download PDF

27. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning

Author

Calais, Jeremie, Czernin, Johannes, Cao, Minsong, Kishan, Amar U, Hegde, John V, Shaverdian, Narek, Sandler, Kiri, Chu, Fang-I, King, Chris R, Steinberg, Michael L, Rauscher, Isabel, Schmidt-Hegemann, Nina-Sophie, Poeppel, Thorsten, Hetkamp, Philipp, Ceci, Francesco, Herrmann, Ken, Fendler, Wolfgang P, Eiber, Matthias, and Nickols, Nicholas G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Prostate Cancer, Urologic Diseases, Radiation Oncology, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Adult, Aged, Aged, 80 and over, Edetic Acid, Gallium Isotopes, Gallium Radioisotopes, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Oligopeptides, Positron Emission Tomography Computed Tomography, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Radiotherapy Planning, Computer-Assisted, Recurrence, Salvage Therapy, prostate cancer, PSMA, PET/CT, recurrence, salvage radiotherapy, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga-labeled prostate-specific membrane antigen (PSMA-11) PET/CT detects recurrent PCa with sensitivity superior to standard-of-care imaging at serum prostate-specific antigen (PSA) values low enough to affect target volume delineations for routine SRT. Our objective was to map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with 68Ga-PSMA-11 PET/CT in patients with serum PSA levels of less than 1 ng/mL, determine how often consensus clinical target volumes (CTVs) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover 68Ga-PSMA-11 PET/CT-defined disease, and assess the potential impact of 68Ga-PSMA-11 PET/CT on SRT. Methods: This was a post hoc analysis of an intention-to-treat population of 270 patients who underwent 68Ga-PSMA-11 PET/CT at 4 institutions for BCR after prostatectomy without prior radiotherapy at a PSA level of less than 1 ng/mL. RTOG consensus CTVs that included both the prostate bed and the pelvic lymph nodes were contoured on the CT dataset of the PET/CT image by a radiation oncologist masked to the PET component. 68Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. 68Ga-PSMA-11-positive lesions not covered by planning volumes based on the consensus CTVs were considered to have a potential major impact on treatment planning. Results: The median PSA level at the time of 68Ga-PSMA-11 PET/CT was 0.48 ng/mL (range, 0.03-1 ng/mL). One hundred thirty-two of 270 patients (49%) had a positive 68Ga-PSMA-11 PET/CT result. Fifty-two of 270 (19%) had at least one PSMA-11-positive lesion not covered by the consensus CTVs. Thirty-three of 270 (12%) had extrapelvic PSMA-11-positive lesions, and 19 of 270 (7%) had PSMA-11-positive lesions within the pelvis but not covered by the consensus CTVs. The 2 most common 68Ga-PSMA-11-positive lesion locations outside the consensus CTVs were bone (23/52, 44%) and perirectal lymph nodes (16/52, 31%). Conclusion: Post hoc analysis of 68Ga-PSMA-11 PET/CT implied a major impact on SRT planning in 52 of 270 patients (19%) with PCa early BCR (PSA < 1.0 ng/mL). This finding justifies a randomized imaging trial of SRT with or without 68Ga-PSMA-11 PET/CT investigating its potential benefit on clinical outcome.

Published
2018

28. Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation

Author

Kroeze, Stephanie G.C., Henkenberens, Christoph, Schmidt-Hegemann, Nina Sophie, Vogel, Marco M.E., Kirste, Simon, Becker, Jessica, Burger, Irene A., Derlin, Thorsten, Bartenstein, Peter, Eiber, Matthias, Mix, Michael, la Fougère, Christian, Christiansen, Hans, Belka, Claus, Combs, Stephanie E., Grosu, Anca L., Müller, Arndt Christian, and Guckenberger, Matthias

Published
2021
Full Text
View/download PDF

29. Radiotherapy in nodal oligorecurrent prostate cancer

Author

Pinkawa, Michael, Aebersold, Daniel M., Böhmer, Dirk, Flentje, Michael, Ghadjar, Pirus, Schmidt-Hegemann, Nina-Sophie, Höcht, Stefan, Hölscher, Tobias, Müller, Arndt-Christian, Niehoff, Peter, Sedlmayer, Felix, Wolf, Frank, Zamboglou, Constantinos, Zips, Daniel, and Wiegel, Thomas

Published
2021
Full Text
View/download PDF

32. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference

Author

Zamboglou, Constantinos, Fassbender, Thomas F., Steffan, Lina, Schiller, Florian, Fechter, Tobias, Carles, Montserrat, Kiefer, Selina, Rischke, Hans C., Reichel, Kathrin, Schmidt-Hegemann, Nina-Sophie, Ilhan, Harun, Chirindel, Alin F., Nicolas, Guillaume, Henkenberens, Christoph, Derlin, Thorsten, Bronsert, Peter, Mavroidis, Panayiotis, Chen, Ronald C., Meyer, Philipp T., Ruf, Juri, and Grosu, Anca L.

Published
2019
Full Text
View/download PDF

33. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy

Author

Vogel, Marco M. E., Kroeze, Stephanie G. C., Henkenberens, Christoph, Schmidt-Hegemann, Nina-Sophie, Kirste, Simon, Becker, Jessica, Burger, Irene A., Derlin, Thorsten, Bartenstein, Peter, Mix, Michael, la Fougère, Christian, Eiber, Matthias, Christiansen, Hans, Belka, Claus, Grosu, Anca L., Müller, Arndt-Christian, Guckenberger, Matthias, and Combs, Stephanie E.

Published
2020
Full Text
View/download PDF

35. Differentiation of benign and metastatic lymph nodes in soft tissue sarcoma

Author

Burkhard-Meier, Anton, primary, Jurinovic, Vindi, additional, Berclaz, Luc M., additional, Albertsmeier, Markus, additional, Dürr, Hans Roland, additional, Klein, Alexander, additional, Knösel, Thomas, additional, Gioia, Dorit Di, additional, Unterrainer, Lena M., additional, Schmidt-Hegemann, Nina-Sophie, additional, Ricke, Jens, additional, Bergwelt-Baildon, Michael, additional, Kunz, Wolfgang G., additional, and Lindner, Lars H., additional

Published
2023
Full Text
View/download PDF

37. 1443: Whole vs. hemi pelvis RT in patients with PSMA-positive nodal recurrence - a retrospective analysis

Author

Trapp, Christian, Aebersold, Daniel M., Belka, Claus, Casuscelli, Jozefina, Ceci, Francesco, Emmett, Louise, Fanti, Stefano, Farolfi, Andrea, Grosu, Anca-Ligia, Guckenberger, Matthias, Henkenberens, Christoph, Hruby, George, Koerber, Stefan A., Kroeze, Stephanie, Peeken, Jan C., Rogowski, Paul, Scharl, Sophia, Shelan, Mohamed, Spohn, Simon K.B., Strouthos, Iosif, Unterrainer, Lena, Vogel, Marco, Wiegel, Thomas, Zamboglou, Constantinos, and Schmidt-Hegemann, Nina-Sophie

Published
2024
Full Text
View/download PDF

39. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer

Author

Zamboglou, Constantinos, primary, Peeken, Jan C., additional, Janbain, Ali, additional, Katsahian, Sandrine, additional, Strouthos, Iosif, additional, Ferentinos, Konstantinos, additional, Farolfi, Andrea, additional, Koerber, Stefan A., additional, Debus, Juergen, additional, Vogel, Marco E., additional, Combs, Stephanie E., additional, Vrachimis, Alexis, additional, Morganti, Alessio Giuseppe, additional, Spohn, Simon K. B., additional, Shelan, Mohamed, additional, Aebersold, Daniel M., additional, Grosu, Anca-Ligia, additional, Ceci, Francesco, additional, Henkenberens, Christoph, additional, Kroeze, Stephanie G. C., additional, Guckenberger, Matthias, additional, Fanti, Stefano, additional, Belka, Claus, additional, Bartenstein, Peter, additional, Hruby, George, additional, Scharl, Sophia, additional, Wiegel, Thomas, additional, Emmett, Louise, additional, Arnoux, Armelle, additional, and Schmidt-Hegemann, Nina-Sophie, additional

Published
2023
Full Text
View/download PDF

40. TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)

Author

Berclaz, Luc M., primary, Altendorf-Hofmann, Annelore, additional, Lindner, Lars H., additional, Burkhard-Meier, Anton, additional, Di Gioia, Dorit, additional, Dürr, Hans Roland, additional, Klein, Alexander, additional, Albertsmeier, Markus, additional, Schmidt-Hegemann, Nina-Sophie, additional, Klauschen, Frederick, additional, and Knösel, Thomas, additional

Published
2023
Full Text
View/download PDF

42. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

Author

Oehus, Ann-Kathrin, Kroeze, Stephanie G. C., Schmidt-Hegemann, Nina-Sophie, Vogel, Marco M. E., Kirste, Simon, Becker, Jessica, Burger, Irene A., Derlin, Thorsten, Bartenstein, Peter, Eiber, Matthias, Mix, Michael, la Fougère, Christian, Belka, Claus, Combs, Stephanie E., Grosu, Anca-Ligia, Müller, Arndt-Christian, Guckenberger, Matthias, Christiansen, Hans, and Henkenberens, Christoph

Published
2020
Full Text
View/download PDF

44. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer

Author

Zamboglou, Constantinos, Peeken, Jan C, Janbain, Ali, Katsahian, Sandrine, Strouthos, Iosif, Ferentinos, Konstantinos, Farolfi, Andrea, Koerber, Stefan A, Debus, Juergen, Vogel, Marco E, Combs, Stephanie E, Vrachimis, Alexis, Morganti, Alessio Giuseppe, Spohn, Simon K B, Shelan, Mohamed, Aebersold, Daniel M, Grosu, Anca-Ligia, Ceci, Francesco, Henkenberens, Christoph, Kroeze, Stephanie G C, Guckenberger, Matthias, Fanti, Stefano, Belka, Claus, Bartenstein, Peter, Hruby, George, Scharl, Sophia, Wiegel, Thomas, Emmett, Louise, Arnoux, Armelle, Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantinos, Peeken, Jan C, Janbain, Ali, Katsahian, Sandrine, Strouthos, Iosif, Ferentinos, Konstantinos, Farolfi, Andrea, Koerber, Stefan A, Debus, Juergen, Vogel, Marco E, Combs, Stephanie E, Vrachimis, Alexis, Morganti, Alessio Giuseppe, Spohn, Simon K B, Shelan, Mohamed, Aebersold, Daniel M, Grosu, Anca-Ligia, Ceci, Francesco, Henkenberens, Christoph, Kroeze, Stephanie G C, Guckenberger, Matthias, Fanti, Stefano, Belka, Claus, Bartenstein, Peter, Hruby, George, Scharl, Sophia, Wiegel, Thomas, Emmett, Louise, Arnoux, Armelle, and Schmidt-Hegemann, Nina-Sophie

Abstract

IMPORTANCE Prostate-specific antigen membrane positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) after radical prostatectomy for patients with recurrent or persistent prostate cancer. OBJECTIVE To develop and validate a nomogram for prediction of freedom from biochemical failure (FFBF) after PSMA-PET-based sRT. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included 1029 patients with prostate cancer treated between July 1, 2013, and June 30, 2020, at 11 centers from 5 countries. The initial database consisted of 1221 patients. All patients had a PSMA-PET scan prior to sRT. Data were analyzed in November 2022. EXPOSURES Patients with a detectable post-radical prostatectomy prostate-specific antigen (PSA) level treated with sRT to the prostatic fossa with or without additional sRT to pelvic lymphatics or concurrent androgen deprivation therapy (ADT) were eligible. MAIN OUTCOMES AND MEASURES The FFBF rate was estimated, and a predictive nomogram was generated and validated. Biochemical relapse was defined as a PSA nadir of 0.2 ng/mL after sRT. RESULTS In the nomogram creation and validation process, 1029 patients (median age at sRT, 70 years [IQR, 64-74 years]) were included and further divided into a training set (n = 708), internal validation set (n = 271), and external outlier validation set (n = 50). The median follow-up was 32 months (IQR, 21-45 months). Based on the PSMA-PET scan prior to sRT, 437 patients (42.5%) had local recurrences and 313 patients (30.4%) had nodal recurrences. Pelvic lymphatics were electively irradiated for 395 patients (38.4%). All patients received sRT to the prostatic fossa: 103 (10.0%) received a dose of less than 66 Gy, 551 (53.5%) received a dose of 66 to 70 Gy, and 375 (36.5%) received a dose of more than 70 Gy. Androgen deprivation therapy was given to 325 (31.6%) patients. On multivariable Cox proportional hazards regression analysis, pre-sRT PSA level (hazard ratio

Published
2023

45. Genomic classifiers in personalized prostate cancer radiation therapy approaches: a systematic review and future perspectives based on international consensus

Author

Tilki, Derya, Spohn, Simon K.B.; Draulans, Cédric; Kishan, Amar U.; Spratt, Daniel; Ross, Ashley; Maurer, Tobias; Berlin, Alejandro; Blanchard, Pierre; Collins, Sean; Bronsert, Peter; Chen, Ronald; Pra, Alan Dal; de Meerleer, Gert; Eade, Thomas; Haustermans, Karin; Hölscher, Tobias; Höcht, Stefan; Ghadjar, Pirus; Davicioni, Elai; Heck, Matthias; Kerkmeijer, Linda G.W.; Kirste, Simon; Tselis, Nikolaos; Tran, Phuoc T.; Pinkawa, Michael; Pommier, Pascal; Deltas, Constantinos; Schmidt-Hegemann, Nina-Sophie; Wiegel, Thomas; Zilli, Thomas; Tree, Alison C.; Qiu, Xuefeng; Murthy, Vedang; Epstein, Jonathan I.; Graztke, Christian; Gao, Xin; Grosu, Anca L.; Kamran, Sophia C.; Zamboglou, Constantinos, Koç University Hospital, School of Medicine, Tilki, Derya, Spohn, Simon K.B.; Draulans, Cédric; Kishan, Amar U.; Spratt, Daniel; Ross, Ashley; Maurer, Tobias; Berlin, Alejandro; Blanchard, Pierre; Collins, Sean; Bronsert, Peter; Chen, Ronald; Pra, Alan Dal; de Meerleer, Gert; Eade, Thomas; Haustermans, Karin; Hölscher, Tobias; Höcht, Stefan; Ghadjar, Pirus; Davicioni, Elai; Heck, Matthias; Kerkmeijer, Linda G.W.; Kirste, Simon; Tselis, Nikolaos; Tran, Phuoc T.; Pinkawa, Michael; Pommier, Pascal; Deltas, Constantinos; Schmidt-Hegemann, Nina-Sophie; Wiegel, Thomas; Zilli, Thomas; Tree, Alison C.; Qiu, Xuefeng; Murthy, Vedang; Epstein, Jonathan I.; Graztke, Christian; Gao, Xin; Grosu, Anca L.; Kamran, Sophia C.; Zamboglou, Constantinos, Koç University Hospital, and School of Medicine

Abstract

Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ?75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and, European Union (EU); Horizon 2020; Research and Innovation Programme; German Federal Ministry of Education and Research (BMBF); ERA PER Joint Funding Call 2019; A.T. acknowledges support from Cancer Research UK (C33589/A28284 and C7224/A28724 CRUK RadNet). This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We thank Fotini Miltiadous for administrative support. ; Funding text 3: Disclosures: A.U.K. reports funding support from grant P50CA09213 from the Prostate Cancer National Institutes of Health Specialized Programs of Research Excellence and grant W81XWH-22-1-0044 from the Department of Defense, as well as grant RSD1836 from the Radiologic Society of North America, the STOP Cancer organization, the Jonsson Comprehensive Cancer Center, and the Prostate Cancer Foundation. C.Z. received funding from the Klaus Tschira foundation, Naslund Medical, and from the German Research Foundation. C.Z. received speaker fees from Johnson & Johnson and Novocure, all outside the submitted work. E.D. is an employee of Veracyte, manufacturer of Decipher. A.R. is a consultant and/or speaker for Astellas, Bayer, Pfizer, Blue Earth, Lantheus, Janssen, Tempus, and Veracyte. X.G. is on the consulting/advisory board for Bayer, Myovant, and Guardant Health.

Published
2023

46. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study

Author

Ilhan, Harun, Kroenke, Markus, Wurzer, Alexander, Unterrainer, Marcus, Heck, Matthias, Belka, Claus, Knorr, Karina, Langbein, Thomas, Rauscher, Isabel, Schmidt-Hegemann, Nina-Sophie, Schiller, Kilian, Bartenstein, Peter, Wester, Hans-Jürgen, and Eiber, Matthias

Subjects
Radiology, Nuclear Medicine and imaging, Clinical Investigation
Abstract

This bicentric, retrospective analysis investigated the efficacy of PET/CT with a novel theranostic prostate-specific membrane antigen (PSMA)--targeting ligand, (18)F-rhPSMA-7, in patients with biochemical recurrence (BCR) of prostate cancer after curative-intent primary radiotherapy. Methods: Datasets from patients with BCR of prostate cancer after external-beam radiation therapy or brachytherapy who underwent (18)F-rhPSMA-7 PET/CT at either Technical University Munich or Ludwig-Maximilians-University Munich were retrospectively reviewed by experienced nuclear medicine physicians and radiologists at both centers. The median injected activity was 299 MBq (range, 204–420 MBq), and the median uptake time was 77 min (range, 46–120 min). All lesions suggestive of recurrent prostate cancer were noted. Detection rates were correlated with patients’ prostate-specific antigen (PSA) level, primary Gleason score, and prior use of androgen-deprivation therapy (ADT). Results: Ninety-seven patients were included (65 at Technical University Munich and 32 at Ludwig-Maximilians-University Munich). The median prescan PSA was 4.19 ng/mL (range, 0.1–159 ng/mL). The primary Gleason score was ≤6 in 19 patients, 7 in 25, ≥8 in 33, and unknown in 20. Thirty patients received ADT in the 6 mo preceding PET/CT. (18)F-rhPSMA-7 identified lesions in 91 of 97 (94%) patients. Detection rates stratified by PSA were 88% (22/25), 97% (30/31), 90% (19/21), and 100% (20/20) for a PSA of

Published
2022

47. Retroperitoneale Weichgewebssarkome: Stellenwert der Radiotherapie

Author

Nieto, Alexander, Albertsmeier, Markus, Werner, Jens, Di Gioia, Dorit, Lindner, Lars H., Rauch, Josefine, Nachbichler, Silke, Belka, Claus, and Schmidt-Hegemann, Nina-Sophie

Abstract

Hintergrund: Retroperitoneale Weichgewebssarkome (RPS) umfassen Tumoren mesenchymalen Ursprungs mit teils gut charakterisierten, histologischen Subtypen und heterogener Prognose. Die STRASS-Studie, welche den Stellenwert einer neoadjuvanten Radiotherapie beim primären RPS untersuchte, lieferte zum ersten Mal Daten in einer Phase-III-Studie. Ziel der Arbeit: Das primäre Ziel der vorliegenden Arbeit ist es, den Stellenwert der neoadjuvanten Strahlentherapie beim RPS nach Veröffentlichung der STRASS-Studie aufzuzeigen. Material und Methode: Wir führten eine nichtsystematische Literatursuche durch, die Ergebnisse retrospektiver Arbeiten wurden in Bezug zu der kürzlich erschienenen STRASS-Studie gesetzt. Ergebnisse: In den zwei größten, die amerikanischen Datenbanken National Cancer Database (NCDB) und Surveillance, Epidemiology, and End Results Program (SEER) umfassenden Analysen konnte eine Verbesserung des Gesamtüberlebens durch die Radiotherapie beim RPS gezeigt werden. Entgegen diesen Ergebnissen fiel die STRASS-Studie für den kombinierten Endpunkt des abdominal-rezidivfreien 3‑Jahres-Überlebens negativ aus. Hier konnten lediglich initial ungeplante Subgruppenanalysen einen Trend für einen Vorteil für Liposarkome sowie niedriggradige Sarkome zeigen, welcher nicht für Leiomyo- und hochgradige Sarkome nachgewiesen werden konnte. Schlussfolgerungen: Auch bei so seltenen Tumoren wie den RPS ist eine randomisierte Studie wie die STRASS-Studie dank internationaler Kooperation möglich. Die Ergebnisse der STRASS-Studie haben den Stellenwert der neoadjuvanten Radiotherapie in der Gesamtheit der Behandlung von RPS relativiert. Ein längeres Follow-up ist insbesondere zur weiteren Beurteilung des Stellenwertes der Radiotherapie bei den Liposarkomen wünschenswert.

Published
2024
Full Text
View/download PDF

49. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Author

Mehrens, Dirk, primary, Kramer, Kristina K.M., additional, Unterrainer, Lena M., additional, Beyer, Leonie, additional, Bartenstein, Peter, additional, Froelich, Matthias F., additional, Tollens, Fabian, additional, Ricke, Jens, additional, Rübenthaler, Johannes, additional, Schmidt-Hegemann, Nina-Sophie, additional, Herlemann, Annika, additional, Unterrainer, Marcus, additional, and Kunz, Wolfgang G., additional

Published
2023
Full Text
View/download PDF

50. Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy

Author

Spohn, Simon KB, primary, Schmidt-Hegemann, Nina-Sophie, additional, Ruf, Juri, additional, Mix, Michael, additional, Benndorf, Matthias, additional, Bamberg, Fabian, additional, Makowski, Marcus R, additional, Kirste, Simon, additional, Rühle, Alexander, additional, Nouvel, Jerome, additional, Sprave, Tanja, additional, Vogel, Marco ME, additional, Galitsnaya, Polina, additional, Gschwend, Juergen E, additional, Gratzke, Christian, additional, Stief, Christian, additional, Loeck, Steffen, additional, Zwanenburg, Alex, additional, Trapp, Christian, additional, Bernhardt, Denise, additional, Nekolla, Stephan G, additional, Li, Minglun, additional, Belka, Claus, additional, Combs, Stephanie E, additional, Eiber, Matthias, additional, Unterrainer, Lena, additional, Unterrainer, Marcus, additional, Bartenstein, Peter, additional, Grosu, Anca L, additional, Zamboglou, Constantinos, additional, and Peeken, Jan C, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results